Gene Therapy Zynteglo denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Zynteglo as Duplicate Therapy — and Why You Can Appeal

Blue Cross Blue Shield may issue a duplicate-therapy denial for Zynteglo (betibeglogene spartacus) when your plan's clinical reviewers determine that an existing treatment in your current regimen already addresses the same therapeutic objective. For a one-time gene therapy treating transfusion-dependent beta-thalassemia, this rationale is almost always clinically flawed: Zynteglo works through a fundamentally different mechanism than chronic transfusion or pharmacologic management, so no reasonable definition of "duplicate" applies once that distinction is documented.

## Why This Denial Is Appealable

A duplicate-therapy finding must be supported by a side-by-side comparison of mechanisms of action, indications, and outcomes. Because Zynteglo is a gene-addition therapy targeting the root cause of beta-thalassemia rather than managing symptoms, your prescriber can directly rebut the equivalence claim with peer-reviewed mechanism-of-action evidence and the FDA-approved prescribing information.

## Federal Appeal Framework

• Internal appeal (Level 1): Required first step under ACA §2719 and ERISA §503. BCBS must decide within 30 days for pre-service denials or 60 days for post-service claims.
• External review: If the internal appeal fails, you have the right to an Independent Review Organization (IRO) review under ACA §2719. The request window is typically 4 months from the final adverse determination — verify the exact deadline on your denial letter.
• Expedited option: If your condition is urgent and delay would seriously jeopardize your health, you may request expedited internal and external review simultaneously, with decisions required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: Pathology or genetic testing confirming transfusion-dependent beta-thalassemia, including genotype documentation. 2. Current treatment history: Complete transfusion records with dates, volumes, and frequency, plus any chelation therapy history with outcomes. 3. Clinical severity: Chart notes documenting disease burden, iron overload assessments, and quality-of-life impact. 4. Mechanism distinction letter: A letter from your hematologist explaining precisely why Zynteglo is not duplicative — it addresses the genetic defect, not just the downstream symptom — referencing the FDA-approved prescribing label. 5. Medical necessity letter: Prescriber's detailed statement of why Zynteglo is medically necessary for this patient at this time.

## Criteria-Mapping Structure

Request a copy of BCBS's published medical policy for Zynteglo and the FDA-approved prescribing label. For each criterion the plan lists as a basis for the duplicate-therapy finding, document the specific chart fact that shows the current therapy is mechanistically distinct. A table format works well:

| Plan Requirement | Chart / Label Evidence | |---|---| | Existing therapy addresses same mechanism | [Hematologist letter explaining gene-addition vs. symptom management] | | Clinical equivalence documented | [FDA label mechanism-of-action section] |

Submit the completed mapping with your internal appeal letter. Reference the applicable hematology/oncology guideline organization (such as the relevant professional society guidelines for beta-thalassemia management) for further support of Zynteglo's distinct clinical role.